INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Scope & Guideline

Unlocking the potential of neuropharmacological breakthroughs.

Introduction

Delve into the academic richness of INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1461-1457
PublisherOXFORD UNIV PRESS
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 1998 to 2024
AbbreviationINT J NEUROPSYCHOPH / Int. J. Neuropsychopharmacol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND

Aims and Scopes

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY serves to advance the understanding of the neurobiological underpinnings of psychiatric disorders and their treatment. It encompasses a broad range of research areas focusing on the interactions between neuropharmacology and psychological processes.
  1. Neuropharmacological Mechanisms:
    Research on the mechanisms of action of various psychotropic medications, including antidepressants, antipsychotics, and emerging therapies like ketamine and psychedelics.
  2. Translational Research in Psychiatry:
    Studies bridging preclinical findings and clinical applications, emphasizing the importance of animal models in understanding human psychiatric conditions.
  3. Neuroinflammation and Mental Health:
    Investigation into the role of neuroinflammatory processes in psychiatric disorders, exploring how inflammation influences mental health outcomes.
  4. Biomarkers and Genetics in Psychiatry:
    Focus on identifying biomarkers for psychiatric disorders and understanding the genetic underpinnings of these conditions, which can inform treatment strategies.
  5. Cognitive and Behavioral Outcomes:
    Exploration of cognitive processes and behavioral outcomes related to psychiatric treatments, including the impact of various interventions on cognitive function.
  6. Substance Use and Addiction:
    Research on the neurobiological aspects of addiction, including the effects of substances like alcohol, nicotine, and illicit drugs on mental health.
The journal has increasingly highlighted several emerging themes, reflecting the current trends in neuropsychopharmacology and psychiatric research.
  1. Psychedelics and Novel Therapeutics:
    There is a growing body of research investigating the therapeutic potential of psychedelics, such as psilocybin and LSD, for treatment-resistant mental health conditions.
  2. Ketamine and Rapid-Acting Antidepressants:
    Research on ketamine's rapid antidepressant effects and its mechanisms is trending, as it offers new hope for patients with treatment-resistant depression.
  3. Neuroinflammation as a Therapeutic Target:
    Emerging studies are focusing on the role of neuroinflammatory processes in psychiatric disorders, highlighting potential new treatment avenues targeting inflammation.
  4. Neuroimaging and Biomarkers:
    The integration of advanced neuroimaging techniques and biomarker identification is on the rise, aiming to personalize treatment strategies based on neurobiological profiles.
  5. Digital Health and Telepsychiatry:
    With the impact of the COVID-19 pandemic, there is an increasing focus on digital health interventions and telepsychiatry, addressing accessibility and treatment delivery.

Declining or Waning

While the journal covers a wide range of topics, some areas have shown a decline in recent publications, indicating a shift in research focus or decreased interest among researchers.
  1. Traditional Pharmacotherapy for Depression:
    Research focused on older classes of antidepressants appears to be declining, with a noticeable shift towards investigating novel treatments, such as ketamine and psychedelics.
  2. Longitudinal Studies in Schizophrenia:
    There has been a decrease in long-term longitudinal studies examining schizophrenia, possibly due to the difficulty in maintaining participant engagement over extended periods.
  3. Behavioral Therapies:
    The focus on non-pharmacological interventions, such as cognitive behavioral therapy (CBT), has diminished in favor of pharmacological approaches and novel treatments.
  4. Neuroanatomical Studies:
    Research concentrating solely on structural neuroimaging without linking to functional outcomes or treatment responses has waned, as integrative approaches gain prominence.

Similar Journals

Current Addiction Reports

Illuminating the path to understanding addiction.
Publisher: SPRINGERNATUREISSN: Frequency: 4 issues/year

Current Addiction Reports, published by SPRINGERNATURE, is a leading journal dedicated to the comprehensive study of addiction in its various dimensions, with a particular focus on the latest clinical developments and research in Clinical Psychology and Psychiatry and Mental Health. Since its inception in 2014 and through to 2024, the journal has established itself as a pivotal resource for researchers, professionals, and students alike, currently holding a prestigious Q1 ranking in both relevant categories. With an impressive Scopus rank of #46 in Clinical Psychology and #129 in Psychiatry and Mental Health, it occupies a significant position within the field, reflecting its commitment to high-quality scholarship and impactful findings. The journal offers open access options, ensuring that vital research is readily available to a global audience. By fostering a deeper understanding of addiction trends and innovative treatment methodologies, Current Addiction Reports plays an essential role in advancing knowledge and improving clinical practices.

NEUROPSYCHOBIOLOGY

Fostering Knowledge: Uniting Neuroscience and Psychological Processes
Publisher: KARGERISSN: 0302-282XFrequency: 6 issues/year

NEUROPSYCHOBIOLOGY, published by KARGER, is a leading academic journal that has been at the forefront of exploring the intricate relationships between neuroscience and psychological processes since its inception in 1975. With both an ISSN of 0302-282X and an E-ISSN of 1423-0224, the journal is renowned for its rigorous peer-reviewed articles and significant contributions to the fields of Biological Psychiatry, Neuropsychology, and Physiological Psychology. Its impact is reflected in its esteemed Scopus rankings, standing out in the 92nd and 81st percentiles in their respective categories. With a commitment to advancing understanding in mental health and neurological science, NEUROPSYCHOBIOLOGY is classified in the Q3 and Q1 quartiles, making it a vital resource for researchers, clinicians, and students alike. Based in Switzerland, the journal embraces a holistic approach to psychological research, bridging gaps between theoretical frameworks and practical applications, thus promoting impactful advancements in the understanding of the human mind.
Explore the latest findings and theories with NEUROPSYCHOBIOLOGY, where your work can contribute to the evolving landscape of neuropsychological studies.

NEUROPHARMACOLOGY

Advancing Knowledge at the Intersection of Neuroscience and Pharmacology
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0028-3908Frequency: 16 issues/year

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Pioneering Research for Tomorrow's Therapeutics
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0278-5846Frequency: 8 issues/year

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

PSYCHIATRY AND CLINICAL NEUROSCIENCES

Advancing the Frontiers of Mental Health and Neurology
Publisher: WILEYISSN: 1323-1316Frequency: 12 issues/year

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

Brain Communications

Illuminating the Complexities of the Human Brain
Publisher: OXFORD UNIV PRESSISSN: Frequency: 1 issue/year

Brain Communications is an esteemed, open-access academic journal published by Oxford University Press since 2019, focusing on the dynamic field of neuroscience. With a dedicated ISSN and an E-ISSN of 2632-1297, this journal aims to address the intricate relationships between brain functions, psychiatric disorders, and neurobiological mechanisms. The journal stands out in the academic realm, holding a prestigious Q1 ranking across several categories, including Biological Psychiatry, Cellular and Molecular Neuroscience, Neurology, and Psychiatry and Mental Health for 2023. Notably, it has also secured impressive Scopus ranks in various neuroscience and psychiatry fields, evidencing its commitment to high-quality research. With an impact factor reflective of its growing influence, Brain Communications provides accessible research findings to professionals, researchers, and students alike, fostering a deeper understanding of complex neurological phenomena. This innovative journal is pivotal for anyone involved in advancing knowledge in neuroscience and mental health.

AMERICAN JOURNAL OF PSYCHIATRY

Shaping the Future of Mental Health Research
Publisher: AMER PSYCHIATRIC PUBLISHING, INCISSN: 0002-953XFrequency: 12 issues/year

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Exploring the Nexus of Biology and Mind.
Publisher: TAYLOR & FRANCIS LTDISSN: 1562-2975Frequency: 8 issues/year

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Advancing the Frontiers of Psychiatry and Neuroscience
Publisher: SPRINGER HEIDELBERGISSN: 0940-1334Frequency: 6 issues/year

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Shaping the Future of Psychiatry with Cutting-Edge Insights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.